Treatment of hearing loss by cord blood stem cells
New clinical study to treat hearing loss by cord blood stem cells has been approved by the FDA:
“Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children”
Acquired sensorineural hearing loss i children will be treated with autologous cord blood cells. The primary objective of this study is to determine the safety of autologous hUCB infusion in children with acquired hearing loss. The secondary objective is to determine if functional, physiologic and anatomic outcomes are improved following hUCB treatment in this patient population.